Panacea Biotec shares jumped 4% in morning trade after Chairman and Managing Director Dr. Rajesh Jain revealed plans to launch a dengue vaccine in the next 2-3 years.
The vaccine, developed in collaboration with the ICMR, is presently undergoing phase three clinical trials at 19 sites in India, covering approximately 10,000 adults.
In a recent interview with CNBC-TV18, Dr. Jain said that the vaccine is making great progress, with clinical trials starting on August 14, 2024. He believes the vaccine to be available within two years, pending regulatory approval. Panacea Biotec’s efforts seek to introduce India’s first dengue vaccine, which would considerably benefit the country’s healthcare industry.
As of 11:07 am, Panacea Biotec shares were trading 4.02% higher at Rs 318.00 on the NSE.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
